| pubmed-article:1918880 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1918880 | lifeskim:mentions | umls-concept:C0229671 | lld:lifeskim |
| pubmed-article:1918880 | lifeskim:mentions | umls-concept:C0205054 | lld:lifeskim |
| pubmed-article:1918880 | lifeskim:mentions | umls-concept:C0178695 | lld:lifeskim |
| pubmed-article:1918880 | lifeskim:mentions | umls-concept:C0005516 | lld:lifeskim |
| pubmed-article:1918880 | lifeskim:mentions | umls-concept:C0151763 | lld:lifeskim |
| pubmed-article:1918880 | lifeskim:mentions | umls-concept:C0205178 | lld:lifeskim |
| pubmed-article:1918880 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:1918880 | pubmed:dateCreated | 1991-11-14 | lld:pubmed |
| pubmed-article:1918880 | pubmed:abstractText | Twenty patients with paracetamol(acetaminophen)-induced acute liver damage of varying severity were studied longitudinally with assessment of clinical state, standard liver function tests and radiometric hyaluronate (HYA) assay (Pharmacia). In patients (n = 6) who developed coma, HYA rose rapidly with clinical deterioration to reach a median value of 27,510 micrograms/l, 7 days post-ingestion, which was significantly higher (p less than 0.005) than in patients (n = 7) who exhibited only marked derangement of liver function tests without evidence of encephalopathy, HYA median value of 3240 micrograms/l. These peak values showed no correlation to the peak values of serum alanine aminotransferase (ALT). A third group of patients (n = 7) who were treated with N-acetyl cysteine, did not exhibit any evidence of liver failure and showed no significant rise in levels of HYA or ALT. The data demonstrate that HYA is a rapidly changing marker of liver derangement which appears to follow the clinical course of the patient. The increase to extremely high levels in patients with hepatic encephalopathy, suggests that there is a reversible defect in the hepatic endothelial cell HYA receptor, possibly due to endothelial cell damage or release of toxins from the necrotic liver. | lld:pubmed |
| pubmed-article:1918880 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1918880 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918880 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1918880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918880 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918880 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1918880 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:1918880 | pubmed:issn | 0168-8278 | lld:pubmed |
| pubmed-article:1918880 | pubmed:author | pubmed-author:LosowskyM SMS | lld:pubmed |
| pubmed-article:1918880 | pubmed:author | pubmed-author:CooperE HEH | lld:pubmed |
| pubmed-article:1918880 | pubmed:author | pubmed-author:ForbesM AMA | lld:pubmed |
| pubmed-article:1918880 | pubmed:author | pubmed-author:RathboneB JBJ | lld:pubmed |
| pubmed-article:1918880 | pubmed:author | pubmed-author:BramleyP NPN | lld:pubmed |
| pubmed-article:1918880 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1918880 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:1918880 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1918880 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1918880 | pubmed:pagination | 8-13 | lld:pubmed |
| pubmed-article:1918880 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:meshHeading | pubmed-meshheading:1918880-... | lld:pubmed |
| pubmed-article:1918880 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1918880 | pubmed:articleTitle | Serum hyaluronate as a marker of hepatic derangement in acute liver damage. | lld:pubmed |
| pubmed-article:1918880 | pubmed:affiliation | Department of Medicine, St. James's University Hospital, Leeds, United Kingdom. | lld:pubmed |
| pubmed-article:1918880 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1918880 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:1918880 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918880 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918880 | lld:pubmed |
